Skip Navigation

Radiopharmaceutical Discovery Lab

RDDL Director, Dr. Mark M. Goodman

RDDL Director, Dr. Mark M. Goodman

Welcome to the Radiopharmaceutical Drug Discovery Lab (RDDL). The goal of the RDDL is to develop radiopharmaceuticals for the study and management of treatment of cancer, cardiovascular disease, cocaine addiction, depression, anxiety, suicide, dementia and psychomotor disorders.

The RDDL is focused on PET and SPECT radiotracer development of cancer imaging agents with special emphasis on fluorine-18, iodine-123 and iodine-124 labeled alicyclic and branched chain amino acids for in vivo mapping of intracranial and systemic tumors. The major distinguishing features of novel imaging technologies developed by the RDDL are the combined use of [18F] labeling, non-metabolized amino acids, and PET and SPECT imaging.

The RDDL has multiple ongoing imaging projects involving the novel [18F] radiolabeled amino acid technology, with the goal of translating this basic imaging research to patients in the clinic. A recent and exciting success story involves the translation of [18F]FACBC from the lab into a diagnostic tool for the management and treatment of brain and prostate cancer.

The successful translation of radiopharmaceuticals by the RDDL hasn’t been limited to cancer. The RDDL developed and translated [123I]BMIPP,  anti-[18F]FACBC,  [18F]FACPC, [18F]FECNT, [123I]MMG-142/IPT, [11C]HOMADAM, [123I]mZIENT and [11C]MENET from the bench to bedside for, heart disorders, cancer, Parkinson’s Disease, cocaine addiction and mood disorders, respectively.

Current endeavors include  the development PET labeled CRF1 antagonists to accelerate drug development of a new class of antidepressants, selective oxytocin receptor antagonists  to probe social behavior, hypoxic inducible factor substrates to accelerate drug development of a new class of anticancer agents,  MR nanoparticles and Hoechst-based agents (DNA binding dyes) to visualize vulnerable plaques and polysaccharides to image infections.

Group Photo